Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03445936 | PRELOOP Trial: Synthetic Versus Biological Mesh for Prevention of Incisional Hernia After Loop-ileostomy Closure | active not recruiting | N/A | 100 | University of OuluOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06143644 | Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence | active not recruiting | — | 220 | Sun Yat-sen UniversityOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04259398 | Anesthesia and Cancer Study: Colon Cancer | active not recruiting | N/A | 797 | Seoul National University HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01678027 | Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication | active not recruiting | Phase 3 | 1,838 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03840239 | TNT to Increase the Clinical Complete Response Rate for Distal LARC(TESS) | active not recruiting | Phase 2 | 98 | Sun Yat-sen UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT06096896 | The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study | active not recruiting | — | 334 | Shandong Provincial HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT03089268 | Molecular and Histological Characteristics of Serrated Lesions of the Colon(SERRACOLON) | active not recruiting | — | 700 | Hospital Universitario La FeOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT04611997 | IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 240 | Fujian Medical UniversityOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04592393 | Pancreas Cancer Surveillance Using an Abbreviated MRI | active not recruiting | N/A | 200 | Seoul National University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05433701 | Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC | active not recruiting | N/A | 178 | Jonggi ChoiOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04764227 | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) | active not recruiting | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04223102 | Microbiome and Rectal Cancer | active not recruiting | N/A | 40 | University of South FloridaOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05951127 | Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC(LEO) | active not recruiting | N/A | 141 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT03347162 | Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer | active not recruiting | — | 1,000 | Rigshospitalet, DenmarkOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03488667 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | active not recruiting | Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT03544736 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | active not recruiting | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT04304209 | Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 195 | Sun Yat-sen UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04833387 | PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer | active not recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT04281667 | Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery(MOBILE2) | active not recruiting | Phase 4 | 604 | Helsinki University Central HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04512937 | Computer Navigation-assisted Surgery for Locally Advanced and Recurrent Rectal Cancer(NAVI-LARRC) | active not recruiting | N/A | 20 | Oslo University HospitalOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03621644 | Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer | active not recruiting | N/A | 133 | Viewray Inc.INDUSTRY | 2 | Oct 14, 2022 | clinicaltrials |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT02113384 | Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells(LARC-EX) | active not recruiting | — | 231 | Oslo University HospitalOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT01688908 | Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)(ESECC) | active not recruiting | N/A | 33,948 | Peking UniversityOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03391843 | Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02482454 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | active not recruiting | Phase 2 / Phase 3 | 50 | The First People's Hospital of ChangzhouOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer(NordICC) | active not recruiting | Phase 3 | 95,000 | Oslo University HospitalOTHER | 6 | Jun 19, 2017 | clinicaltrials |
| NCT02496273 | Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer | active not recruiting | Phase 1 | 60 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 22, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Feb 1, 2024source: clinicaltrials